Advanced

Gemcitabine Treatment in Pancreatic Cancer – Prognostic Factors and Outcome.

Andersson, Bodil LU ; Aho, Ursula LU ; Pendse, Marie-Louise; Nilsson, Johan LU ; Tingstedt, Bobby LU and Andersson, Roland LU (2007) In Annals of Gastroenterology 20(2). p.130-137
Abstract
Background: Pancreatic cancer is generally associated with

a poor prognosis and often diagnosed in an advanced stage.

The aim of the present study was to evaluate gemcitabine

treatment concerning prognostic factors, clinical benefit, tolerance/

toxicity and survival. Methods: Patients with surgically

nonresectable, locally advanced or metastatic pancreatic

cancer treated with gemcitabine were included. Different

parameters, including clinical benefit, toxicity (WHO΄s criteria)

and survival were registered. Kaplan-Meier and Cox

regression analysis were performed. Results: Forty-two consecutive

patients were included. Median age was 62.5 ... (More)
Background: Pancreatic cancer is generally associated with

a poor prognosis and often diagnosed in an advanced stage.

The aim of the present study was to evaluate gemcitabine

treatment concerning prognostic factors, clinical benefit, tolerance/

toxicity and survival. Methods: Patients with surgically

nonresectable, locally advanced or metastatic pancreatic

cancer treated with gemcitabine were included. Different

parameters, including clinical benefit, toxicity (WHO΄s criteria)

and survival were registered. Kaplan-Meier and Cox

regression analysis were performed. Results: Forty-two consecutive

patients were included. Median age was 62.5 years,

42% were men. Gemcitabine treatment lasted in median for 5

months (0.5-29 months). Median survival from diagnosis was

9.4 months and from start of treatment 8.1 months. Thirteen

patients (32%) were alive 12 months after treatment start.

The treatment was overall well tolerated concerning toxicity.

Seven patients had transient grade 4 reactions. Of 8 parameters

selected from the univariate analysis, 3 were identified

as independent predictors for longer survival: age >60

years, ≤5 % weight loss at diagnosis and absence of metastases.

Conclusions: Gemcitabine treatment in locally advanced

and metastatic pancreatic cancer showed to be of potential

benefit and well tolerated. Age, weight loss and metastases

were independent prognostic factors for survival. The median

survival time was longer than previously reported.

Keywords: pancreatic cancer; locally advanced; gemcitabine;

treatment outcome; prognostic factors (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of Gastroenterology
volume
20
issue
2
pages
130 - 137
publisher
Hellenic Society of Gastroenterology
external identifiers
  • scopus:34548526496
ISSN
1108-7471
language
English
LU publication?
yes
id
7bc6276e-8f2b-4bc4-9a10-293edad5ed80 (old id 1141394)
alternative location
http://www.annalsgastro.gr/index.php/annalsgastro/article/view/576/446
date added to LUP
2008-04-29 12:14:46
date last changed
2017-01-01 07:20:19
@article{7bc6276e-8f2b-4bc4-9a10-293edad5ed80,
  abstract     = {Background: Pancreatic cancer is generally associated with<br/><br>
a poor prognosis and often diagnosed in an advanced stage.<br/><br>
The aim of the present study was to evaluate gemcitabine<br/><br>
treatment concerning prognostic factors, clinical benefit, tolerance/<br/><br>
toxicity and survival. Methods: Patients with surgically<br/><br>
nonresectable, locally advanced or metastatic pancreatic<br/><br>
cancer treated with gemcitabine were included. Different<br/><br>
parameters, including clinical benefit, toxicity (WHO΄s criteria)<br/><br>
and survival were registered. Kaplan-Meier and Cox<br/><br>
regression analysis were performed. Results: Forty-two consecutive<br/><br>
patients were included. Median age was 62.5 years,<br/><br>
42% were men. Gemcitabine treatment lasted in median for 5<br/><br>
months (0.5-29 months). Median survival from diagnosis was<br/><br>
9.4 months and from start of treatment 8.1 months. Thirteen<br/><br>
patients (32%) were alive 12 months after treatment start.<br/><br>
The treatment was overall well tolerated concerning toxicity.<br/><br>
Seven patients had transient grade 4 reactions. Of 8 parameters<br/><br>
selected from the univariate analysis, 3 were identified<br/><br>
as independent predictors for longer survival: age &gt;60<br/><br>
years, ≤5 % weight loss at diagnosis and absence of metastases.<br/><br>
Conclusions: Gemcitabine treatment in locally advanced<br/><br>
and metastatic pancreatic cancer showed to be of potential<br/><br>
benefit and well tolerated. Age, weight loss and metastases<br/><br>
were independent prognostic factors for survival. The median<br/><br>
survival time was longer than previously reported.<br/><br>
Keywords: pancreatic cancer; locally advanced; gemcitabine;<br/><br>
treatment outcome; prognostic factors},
  author       = {Andersson, Bodil and Aho, Ursula and Pendse, Marie-Louise and Nilsson, Johan and Tingstedt, Bobby and Andersson, Roland},
  issn         = {1108-7471},
  language     = {eng},
  number       = {2},
  pages        = {130--137},
  publisher    = {Hellenic Society of Gastroenterology},
  series       = {Annals of Gastroenterology},
  title        = {Gemcitabine Treatment in Pancreatic Cancer – Prognostic Factors and Outcome.},
  volume       = {20},
  year         = {2007},
}